Welling Theodore H, Lu Guanyi, Csencsits Keri, Wood Sherri C, Jarvinen Lamis, Bishop D Keith
Department of Surgery, University of Michigan School of Medicine, Ann Arbor, Mich, USA.
Surgery. 2008 Mar;143(3):394-403. doi: 10.1016/j.surg.2007.09.040. Epub 2007 Dec 21.
The cyclin-dependent kinase (cdk) inhibitor p21 inhibits cellular proliferation of many cell types, including T cells. Autoimmune models, however, have yielded conflicting results regarding the role of cdk inhibitors and T-cell function. The role of p21 in T-cell function after transplantation has not been investigated directly. We hypothesized that p21 plays an important role in alloantigen-driven responses in vitro in mixed lymphocyte cultures (MLC) and in vivo using the heterotopic murine cardiac allograft model.
Wild type (WT) and p21-deficient (p21-/-) mice were used as recipients, and the effects of p21 overexpression were assessed by transplanting p21 adenoviral-transfected cardiac allografts. Enzyme-linked immunospot (ELISPOT) and 3H-thymidine incorporation were used to evaluate for T-cell priming and proliferation in vitro, whereas graft histology was evaluated for rejection.
When stimulated with alloantigens in vitro, splenocytes from p21-/- mice mounted enhanced proliferative responses and decreased Th2 responses relative to their WT counterparts. No differences in Th1 responses were noted when p21-/- cells were stimulated with alloantigens in vitro; however, after cardiac transplantation, Th1 responses were enhanced in p21-/- recipients relative to WT mice. This enhanced in vivo Th1 response was associated with exacerbated graft rejection in p21-/- recipients. Interestingly, p21 transfection of WT allografts inhibited graft rejection and Th1 priming.
p21 controls the intensity of the immune response posttransplantation, with overexpression inhibiting allograft rejection. Our data demonstrate that p21 controls T-cell priming and suggest that p21 and other cdk inhibitors may serve as potential targets for therapeutic manipulation of alloimmune responses.
细胞周期蛋白依赖性激酶(cdk)抑制剂p21可抑制包括T细胞在内的多种细胞类型的细胞增殖。然而,在自身免疫模型中,关于cdk抑制剂与T细胞功能的作用产生了相互矛盾的结果。p21在移植后T细胞功能中的作用尚未得到直接研究。我们假设p21在体外混合淋巴细胞培养(MLC)以及使用异位小鼠心脏同种异体移植模型的体内同种异体抗原驱动的反应中起重要作用。
使用野生型(WT)和p21缺陷型(p21-/-)小鼠作为受体,并通过移植p21腺病毒转染的心脏同种异体移植物来评估p21过表达的影响。酶联免疫斑点(ELISPOT)和3H-胸腺嘧啶核苷掺入法用于评估体外T细胞启动和增殖,而移植组织学则用于评估排斥反应。
在体外受到同种异体抗原刺激时,相对于WT小鼠,p21-/-小鼠的脾细胞产生增强的增殖反应和降低的Th2反应。当p21-/-细胞在体外受到同种异体抗原刺激时,未观察到Th1反应的差异;然而,心脏移植后,相对于WT小鼠,p21-/-受体中的Th1反应增强。这种体内Th1反应的增强与p21-/-受体中加剧的移植排斥反应相关。有趣的是,WT同种异体移植物的p21转染抑制了移植排斥反应和Thl启动。
p21控制移植后免疫反应的强度,过表达可抑制同种异体移植排斥反应。我们的数据表明p21控制T细胞启动,并提示p21和其他cdk抑制剂可能作为同种免疫反应治疗性调控的潜在靶点。